ATE519502T1 - Kohlenhydratkonjugate zur verhinderung des missbrauchs kontrollierter substanzen - Google Patents

Kohlenhydratkonjugate zur verhinderung des missbrauchs kontrollierter substanzen

Info

Publication number
ATE519502T1
ATE519502T1 AT04701730T AT04701730T ATE519502T1 AT E519502 T1 ATE519502 T1 AT E519502T1 AT 04701730 T AT04701730 T AT 04701730T AT 04701730 T AT04701730 T AT 04701730T AT E519502 T1 ATE519502 T1 AT E519502T1
Authority
AT
Austria
Prior art keywords
abuse
substance
preventing
controlled substance
controlled substances
Prior art date
Application number
AT04701730T
Other languages
English (en)
Inventor
Travis Mickle
Thomas Piccariello
James Moncrief
Nancy Boerth
Barney Bishop
Original Assignee
Shire Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shire Llc filed Critical Shire Llc
Application granted granted Critical
Publication of ATE519502T1 publication Critical patent/ATE519502T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/485Morphinan derivatives, e.g. morphine, codeine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549Sugars, nucleosides, nucleotides or nucleic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/26Psychostimulants, e.g. nicotine, cocaine

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Biochemistry (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Paper (AREA)
  • Steroid Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT04701730T 2003-01-13 2004-01-13 Kohlenhydratkonjugate zur verhinderung des missbrauchs kontrollierter substanzen ATE519502T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43946803P 2003-01-13 2003-01-13
PCT/US2004/000646 WO2004062614A2 (en) 2003-01-13 2004-01-13 Carbohydrate conjugates to prevent abuse of controlled substances

Publications (1)

Publication Number Publication Date
ATE519502T1 true ATE519502T1 (de) 2011-08-15

Family

ID=32713487

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04701730T ATE519502T1 (de) 2003-01-13 2004-01-13 Kohlenhydratkonjugate zur verhinderung des missbrauchs kontrollierter substanzen

Country Status (10)

Country Link
EP (1) EP1594513B1 (de)
JP (1) JP2006515622A (de)
KR (1) KR20050098246A (de)
CN (1) CN1747737A (de)
AT (1) ATE519502T1 (de)
AU (1) AU2004204804C1 (de)
CA (1) CA2512951A1 (de)
ES (1) ES2371462T3 (de)
IL (1) IL169645A0 (de)
WO (1) WO2004062614A2 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7943586B2 (en) 2003-06-09 2011-05-17 The Trustees Of The University Of Pennsylvania Antineoplastic agents targeted via glut transporters
CA2653741C (en) * 2006-05-26 2015-07-07 Thomas E. Jenkins Controlled release of phenolic opioids
CA2707980C (en) 2007-12-17 2015-05-12 Labopharm Inc. Misuse preventative, controlled release formulation
EP2367541B1 (de) 2008-12-16 2014-07-16 Paladin Labs Inc. Formulierung mit gesteuerter freisetzung und missbrauchsschutz
US9808452B2 (en) 2015-10-01 2017-11-07 Elysium Therapeutics, Inc. Polysubunit opioid prodrugs resistant to overdose and abuse
US10335406B2 (en) 2015-10-01 2019-07-02 Elysium Therapeutics, Inc. Opioid compositions resistant to overdose and abuse
JP7234130B2 (ja) 2017-03-17 2023-03-07 エリージウム セラピューティクス, インコーポレイテッド 過剰摂取および乱用に対して抵抗性のポリサブユニットオピオイドプロドラッグ
CN116115768B (zh) * 2022-12-01 2025-03-18 西南民族大学 一种抗菌剂及其制备方法和应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6548484B1 (en) * 2000-04-12 2003-04-15 International Medical Innovations, Inc. Pharmaceutical dopamine glycoconjugate compositions and methods of their preparation
US20030130205A1 (en) * 2000-04-12 2003-07-10 Christian Samuel T. Novel pharmaceutical anti-infective agents containing carbohydrate moieties and methods of their preparation and use
US20020099013A1 (en) * 2000-11-14 2002-07-25 Thomas Piccariello Active agent delivery systems and methods for protecting and administering active agents
EP1325014B1 (de) * 2000-09-22 2012-05-23 JPI Commercial, LLC Gamma-hydroxybutyratzusammensetzungen mit kohlenhydratträger
AU2002313628A1 (en) * 2001-05-22 2002-12-03 Euro-Celtique Tamper resistant oral dosage form
US6713452B2 (en) * 2001-06-04 2004-03-30 Nobex Corporation Mixtures of calcitonin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
WO2003057716A2 (en) * 2002-01-08 2003-07-17 New River Pharmaceuticals, Inc. Dendritic encapsulation of active agents
JP4878732B2 (ja) * 2002-02-22 2012-02-15 シャイア エルエルシー 規制物質の濫用を防ぐための新規な持続放出製薬化合物
EP1575569B1 (de) * 2002-12-13 2010-09-29 Durect Corporation Orale darreichungsform mit flüssigen hochviskosen trägersystemen

Also Published As

Publication number Publication date
KR20050098246A (ko) 2005-10-11
EP1594513A4 (de) 2009-02-04
JP2006515622A (ja) 2006-06-01
CA2512951A1 (en) 2004-07-29
EP1594513A2 (de) 2005-11-16
CN1747737A (zh) 2006-03-15
WO2004062614A3 (en) 2005-05-06
AU2004204804A1 (en) 2004-07-29
EP1594513B1 (de) 2011-08-10
WO2004062614A2 (en) 2004-07-29
AU2004204804B2 (en) 2010-06-24
IL169645A0 (en) 2007-07-04
ES2371462T3 (es) 2012-01-03
AU2004204804C1 (en) 2010-11-18

Similar Documents

Publication Publication Date Title
SG155054A1 (en) Human anti- neutralizing antibodies as selective pathway inhibitors
DK1075282T3 (da) PEG-LHRH-analog-konjugater
SG164369A1 (en) Human anti-b7rp1 neutralizing antibodies
EP1796666A4 (de) Verfahren und zusammensetzungen zur behandlung von hyperlipidämie
EP0740650A4 (de) Kombinierte wirkstoffe als methode zur gezielten wirkstoff-freisetzung
UA85993C2 (ru) Конъюгат, который содержит бактериальный суперантиген и антительную составную, фармацевтическая композиция, которая его содержит, и способ лечения рака у млекопитающего
ATE339406T1 (de) Chinazoline verbindungen als heilmittel
AU2002324914A1 (en) Pharmaceutical compositions of drug-oligomer conjugates and methods of treating diseases therewith
EP2353611A3 (de) Arzneimittelkonjugate und deren Verwendung zur Behandlung von Krebs, einer Autoimmunerkrankung oder einer Infektionskrankheit
BR0110530A (pt) Composições farmacêuticas contendo um antibiótico glicopeptìdico e uma ciclodextrina
MY137828A (en) Keratinocytes which may be used as a biologically active substances for the treatment of wounds
EP1505990A4 (de) Verfahren zur behandlung von hepatitis
BRPI0410049A (pt) composto ou um sal ou estereoisÈmero farmaceuticamente aceitável do mesmo, uso de um composto, composição farmacêutica, e, kit farmacêutico
EP1572118A4 (de) Verfahren und zusammensetzungen zur behandlung von krebs mit 15986, 2188, 20743, 9148, 9151, 9791, 44252, 14184, 42461, 8204, 7970, 25552, 21657, 26492, 2411, 15088, 1905, 28899, 63380, 33935, 10480, 12686, 25501, 17694, 15701, 53062, 49908, 21612, 38949, 6216, 46863, 9235, 2201, 6985, 9883, 12238, 18057, 216
ATE519502T1 (de) Kohlenhydratkonjugate zur verhinderung des missbrauchs kontrollierter substanzen
GB2431346B (en) A combination composition comprising paracetamol and ibuprofen
EP1978034A4 (de) Antiperiostin-antikörper und pharmazeutische zusammensetzung zur prävention oder behandlung von mit periostin in zusammenhang stehenden krankheiten, die diese enthält
EP1512405A4 (de) Zusammensetzung zur linderung von chloasma und zusammensetzung zur linderung von stumpfem aussehen
WO2007005941A3 (en) Liver targeted conjugates
DE60027905D1 (de) Glycokonjugate, glycoaminosäure, deren zwischenprodukte, und ihre verwendung
TW200806293A (en) Methods of treatment with CETP inhibitors
PT1165159E (pt) Suportes oligossacarídicos para e.g. a remoção de anticorpos do sangue
FR2877576B1 (fr) Composition pharmaceutique utilisee pour stimuler la proliferation et l'activation des mastocytes
DE10081194D2 (de) Darreichungsform zur Applikation in Körperöffnungen
DE602006013009D1 (de) Pharmazeutische zusammensetzung von mahanin zur behandlung von prostatakrebs

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties